Intra Cellular Therapies | 应收帐款人



应收帐款人 更改 日
Acadia Pharmaceuticals USD 139.44M 19.75M 2025-09
ALKERMES USD 355.11M 1.22M 2025-09
BioCryst Pharmaceuticals USD 79.07M 6.61M 2024-12
Biogen USD 1.85B 234M 2025-09
Bristol-Myers Squibb USD 14.62B 485M 2025-09
Cytokinetics USD 1.81M 6.6M 2025-09
Esperion Therapeutics USD 60.36M 5.75M 2024-06
Gilead Sciences USD 4.91B 182M 2025-12
Halozyme Therapeutics USD 441.27M 95.24M 2025-12
J&J USD 17.61B 235M 2025-09
Nektar Therapeutics USD 0 2.9M 2024-09
Neurocrine Biosciences USD 686.8M 41.2M 2025-12
Novartis USD 8.98B 192M 2025-09
Prothena USD 5.16M 0 2023-12
RedHill Biopharma USD 5.35M 1.78M 2025-06
Supernus Pharmaceuticals USD 171.25M 30.42M 2025-09
United Therapeutics USD 297.7M 81.6M 2025-09
Vanda Pharmaceuticals USD 47.1M 4.35M 2024-12


Intra Cellular Therapies 应收帐款人 - 当前值，历史数据，预测，统计，图表和经济日历 - Feb 2026.